Loading
Founded cancer neuroscience and led the GD2 CAR-T trial that produced the first regressions of diffuse midline glioma.
Michelle Monje showed that neuronal activity drives glioma growth through neuroligin-3 and synaptic integration, founding the field of cancer neuroscience, and led the first-in-human trial of GD2-directed CAR T cells in H3K27M-mutant diffuse midline glioma that produced radiographic and clinical improvements in a disease with no effective therapy. She was awarded a MacArthur Fellowship and leads paediatric neuro-oncology research at Stanford.
Shares CAR-T cell therapy and the tags paediatric, car-t.
Shares CAR-T cell therapy and the tags paediatric, car-t.
Shares Stanford Health Care / Stanford Cancer Institute, CAR-T cell therapy.
Shares the tags paediatric, glioma.
Shares CAR-T cell therapy and the tag car-t.
Shares CAR-T cell therapy and the tag car-t.
Shares Stanford Health Care / Stanford Cancer Institute, CAR-T cell therapy.
Shares CAR-T cell therapy and the tag paediatric.